UPDATE: Jefferies Raises PT on Bristol-Myers Squibb on Positive Outlook

In a report published Wednesday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Bristol-Myers Squibb Co. (NYSE: BMY ), and raised the price target from $41.00 to $45.00. In the report, Holford noted, “We remain positive on Pharmaceuticals and see valuation as attractive for most stocks. Our Top Pick